home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

CMC Regulatory Compliance for Biopharmaceuticals and Biologics

 
  January 06, 2012  
     
 
Center for Professional Innovation & Education (CfPIE), King of Prussia, PA
June 20 22, 2012


CMC regulatory compliance deficiencies have resulted in clinical holds and delays in market approval. Additionally, CMC regulatory shortfalls in marketed products have also resulted in FDA Warning Letters and product recalls. Insights and practical suggestions to develop and manage CMC regulatory compliance for biopharmaceuticals and biologics are presented in this class.This three-day course will also present a strategy to obtain a cost-effective, risk-managed CMC compliance strategy particularly useful for all stages of clinical development, and for those biopharmaceutical and biologic products already on the market. This course also includes a discussion on preparing the CMC sections for a market application dossier using the Common Technical Document (CTD)-formatted Modules 2.3 and 3 for biopharmaceuticals and biologics.
 
 
Organized by: Center for Professional Innovation & Education
Invited Speakers: Contact info@cfpie.com for a list of course instructors
 
Deadline for Abstracts: n/a
 
Registration: http://www.cfpie.com/showitem.aspx?productid=017&source=hummolgen
E-mail: info@cfpie.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.